Skip to main content
Erschienen in: Clinical & Experimental Metastasis 8/2009

01.12.2009 | Research Paper

Modulation of prostate cancer cell gene expression by cell-to-cell contact with bone marrow stromal cells or osteoblasts

verfasst von: Shuming Zhang, Jun Wang, Mehmet A. Bilen, Sue-Hwa Lin, Samuel I. Stupp, Robert L. Satcher

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 8/2009

Einloggen, um Zugang zu erhalten

Abstract

After prostate cancer cells (PCa) arrive in bone, interactions with cells that include long bone osteoblasts (LBOB) and bone marrow stromal cells (BMSC) lead to metastasis formation. The effect of heterotypic cell–cell contact between PCa cells and BMSC or LBOB on PCa cell gene expression is poorly understood. To establish the role of heterotypic contact in bone metastasis formation, we mixed and co-cultured PC3 cells with rat BMSC, LBOB, or human prostate stromal cells (PS15). PC3 cells were then re-isolated for gene array analysis, and imaged using in situ hybridization to confirm that heterotypic contact regulates gene expression. The gene expression was examined using focused gene arrays containing 96 each of tumor metastasis genes or osteogenesis genes. A total of 18 out of 192 genes in PC3 cells were found to be under or over expressed subsequent to heterotypic contact with BMSC when analyzed. A total of 15 genes out of 192 were regulated in co-culture with LBOB, and 19 genes with PS15. Only two genes, uPA and Collagen III, were regulated by contact with BMSC or LBOB (both are bone derived cells), but not by contact with PS15. The relationship between cell–cell contact and uPA expression was further explored by varying cell ratios in co-culture. uPA over-expression in PC3 was related to the BMSC:PC3 ratio, and was maximum at a 10:1 ratio, where most PC3 cells would be in contact with BMSC, as predicted by a theoretical model of heterotypic contact. In situ staining of micropatterned PC3 and BMSC cells showed that uPA over-expression localizes to regions of heterotypic cell–cell contact. Taken together, our results suggest that heterotypic cell-to-cell contact between PC3 and BMSC proportionally enhances gene expression for uPA, providing a mechanism for localized control of invasiveness.
Literatur
1.
Zurück zum Zitat Zhang X, Jin TG, Yang H et al (2004) Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 64(19):7086–7091CrossRefPubMed Zhang X, Jin TG, Yang H et al (2004) Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 64(19):7086–7091CrossRefPubMed
2.
Zurück zum Zitat Shah RB, Mehra R, Chinnaiyan AM et al (2004) Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64(24):9209–9216CrossRefPubMed Shah RB, Mehra R, Chinnaiyan AM et al (2004) Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64(24):9209–9216CrossRefPubMed
3.
Zurück zum Zitat Kim SJ, Uehara H, Karashima T et al (2003) Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 9(3):1200–1210PubMed Kim SJ, Uehara H, Karashima T et al (2003) Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 9(3):1200–1210PubMed
4.
Zurück zum Zitat Kim SJ, Uehara H, Yazici S et al (2004) Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res 64(12):4201–4208CrossRefPubMed Kim SJ, Uehara H, Yazici S et al (2004) Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res 64(12):4201–4208CrossRefPubMed
5.
Zurück zum Zitat Patel P, Ashdown D, James N (2004) Is gene therapy the answer for prostate cancer? Prostate Cancer Prostatic Dis 7(Suppl 1):S14–S19CrossRefPubMed Patel P, Ashdown D, James N (2004) Is gene therapy the answer for prostate cancer? Prostate Cancer Prostatic Dis 7(Suppl 1):S14–S19CrossRefPubMed
6.
Zurück zum Zitat Harms JF, Welch DR (2003) MDA-MB-435 human breast carcinoma metastasis to bone. Clin Exp Metastasis 20(4):327–334CrossRefPubMed Harms JF, Welch DR (2003) MDA-MB-435 human breast carcinoma metastasis to bone. Clin Exp Metastasis 20(4):327–334CrossRefPubMed
7.
Zurück zum Zitat Rosol TJ, Tannehill-Gregg SH, LeRoy BE et al (2003) Animal models of bone metastasis. Cancer 97(3 Suppl):748–757CrossRefPubMed Rosol TJ, Tannehill-Gregg SH, LeRoy BE et al (2003) Animal models of bone metastasis. Cancer 97(3 Suppl):748–757CrossRefPubMed
8.
Zurück zum Zitat Festuccia C, Angelucci A, Gravina GL et al (2000) Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells. Int J Cancer 85(3):407–415CrossRefPubMed Festuccia C, Angelucci A, Gravina GL et al (2000) Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells. Int J Cancer 85(3):407–415CrossRefPubMed
9.
Zurück zum Zitat Hart CA, Scott LJ, Bagley S et al (2002) Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies. Br J Cancer 86(7):1136–1142CrossRefPubMed Hart CA, Scott LJ, Bagley S et al (2002) Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies. Br J Cancer 86(7):1136–1142CrossRefPubMed
10.
Zurück zum Zitat Lang SH, Clarke NW, George NJ et al (1998) Interaction of prostate epithelial cells from benign and malignant tumor tissue with bone-marrow stroma. Prostate 34(3):203–213CrossRefPubMed Lang SH, Clarke NW, George NJ et al (1998) Interaction of prostate epithelial cells from benign and malignant tumor tissue with bone-marrow stroma. Prostate 34(3):203–213CrossRefPubMed
11.
Zurück zum Zitat Millimaggi D, Festuccia C, Angelucci A et al (2006) Osteoblast-conditioned media stimulate membrane vesicle shedding in prostate cancer cells. Int J Oncol 28(4):909–914PubMed Millimaggi D, Festuccia C, Angelucci A et al (2006) Osteoblast-conditioned media stimulate membrane vesicle shedding in prostate cancer cells. Int J Oncol 28(4):909–914PubMed
12.
Zurück zum Zitat Wang J, Levenson AS, Satcher RL Jr (2006) Identification of a unique set of genes altered during cell–cell contact in an in vitro model of prostate cancer bone metastasis. Int J Mol Med 17(5):849–856PubMed Wang J, Levenson AS, Satcher RL Jr (2006) Identification of a unique set of genes altered during cell–cell contact in an in vitro model of prostate cancer bone metastasis. Int J Mol Med 17(5):849–856PubMed
13.
Zurück zum Zitat Nauman EA, Satcher RL, Keaveny TM et al (2001) Osteoblasts respond to pulsatile fluid flow with short-term increases in PGE(2) but no change in mineralization. J Appl Physiol 90(5):1849–1854PubMed Nauman EA, Satcher RL, Keaveny TM et al (2001) Osteoblasts respond to pulsatile fluid flow with short-term increases in PGE(2) but no change in mineralization. J Appl Physiol 90(5):1849–1854PubMed
14.
Zurück zum Zitat Hung CT, Pollack SR, Reilly TM et al (1995) Real-time calcium response of cultured bone cells to fluid flow. Clin Orthop Relat Res (313):256–269 Hung CT, Pollack SR, Reilly TM et al (1995) Real-time calcium response of cultured bone cells to fluid flow. Clin Orthop Relat Res (313):256–269
15.
Zurück zum Zitat Kassen A, Sutkowski DM, Ahn H et al (1996) Stromal cells of the human prostate: initial isolation and characterization. Prostate 28(2):89–97CrossRefPubMed Kassen A, Sutkowski DM, Ahn H et al (1996) Stromal cells of the human prostate: initial isolation and characterization. Prostate 28(2):89–97CrossRefPubMed
16.
Zurück zum Zitat Sensibar JA, Pruden SJ, Kasjanski RZ et al (1999) Differential growth rates in stromal cultures of human prostate derived from patients of varying ages. Prostate 38(2):110–117CrossRefPubMed Sensibar JA, Pruden SJ, Kasjanski RZ et al (1999) Differential growth rates in stromal cultures of human prostate derived from patients of varying ages. Prostate 38(2):110–117CrossRefPubMed
17.
Zurück zum Zitat Satcher RL Jr, Dvorkin K, Levenson AS et al (2004) Gene expression in cancer cells is influenced by contact with bone cells in a novel coculture system that models bone metastasis. Clin Orthop Relat Res (426):54–63 Satcher RL Jr, Dvorkin K, Levenson AS et al (2004) Gene expression in cancer cells is influenced by contact with bone cells in a novel coculture system that models bone metastasis. Clin Orthop Relat Res (426):54–63
18.
Zurück zum Zitat Paget S (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8(2):98–101PubMed Paget S (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8(2):98–101PubMed
19.
Zurück zum Zitat Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584–593CrossRefPubMed Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584–593CrossRefPubMed
20.
Zurück zum Zitat Sung SY, Chung LW (2002) Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation 70(9–10):506–521CrossRefPubMed Sung SY, Chung LW (2002) Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation 70(9–10):506–521CrossRefPubMed
21.
Zurück zum Zitat Hart CA, Brown M, Bagley S et al (2005) Invasive characteristics of human prostatic epithelial cells: understanding the metastatic process. Br J Cancer 92(3):503–512PubMed Hart CA, Brown M, Bagley S et al (2005) Invasive characteristics of human prostatic epithelial cells: understanding the metastatic process. Br J Cancer 92(3):503–512PubMed
22.
Zurück zum Zitat Andreasen PA, Kjoller L, Christensen L et al (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72(1):1–22CrossRefPubMed Andreasen PA, Kjoller L, Christensen L et al (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72(1):1–22CrossRefPubMed
23.
Zurück zum Zitat Festuccia C, Dolo V, Guerra F et al (1998) Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis 16(6):513–528CrossRefPubMed Festuccia C, Dolo V, Guerra F et al (1998) Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis 16(6):513–528CrossRefPubMed
24.
Zurück zum Zitat Margheri F, D’Alessio S, Serrati S et al (2005) Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases. Gene Ther 12(8):702–714CrossRefPubMed Margheri F, D’Alessio S, Serrati S et al (2005) Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases. Gene Ther 12(8):702–714CrossRefPubMed
25.
Zurück zum Zitat Pulukuri SM, Gondi CS, Lakka SS et al (2005) RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 280(43):36529–36540CrossRefPubMed Pulukuri SM, Gondi CS, Lakka SS et al (2005) RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 280(43):36529–36540CrossRefPubMed
26.
Zurück zum Zitat Angelucci A, Gravina GL, Rucci N et al (2006) Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer 13(1):197–210CrossRefPubMed Angelucci A, Gravina GL, Rucci N et al (2006) Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer 13(1):197–210CrossRefPubMed
27.
Zurück zum Zitat Benasciutti E, Pages G, Kenzior O et al (2004) MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription. Blood 104(1):256–262CrossRefPubMed Benasciutti E, Pages G, Kenzior O et al (2004) MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription. Blood 104(1):256–262CrossRefPubMed
28.
Zurück zum Zitat Bhatia SN, Balis UJ, Yarmush ML et al (1999) Effect of cell–cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. Faseb J 13(14):1883–1900PubMed Bhatia SN, Balis UJ, Yarmush ML et al (1999) Effect of cell–cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. Faseb J 13(14):1883–1900PubMed
29.
Zurück zum Zitat Chung LW, Baseman A, Assikis V et al (2005) Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 173(1):10–20PubMed Chung LW, Baseman A, Assikis V et al (2005) Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 173(1):10–20PubMed
30.
Zurück zum Zitat Siggelkow H, Rebenstorff K, Kurre W et al (1999) Development of the osteoblast phenotype in primary human osteoblasts in culture: comparison with rat calvarial cells in osteoblast differentiation. J Cell Biochem 75(1):22–35CrossRefPubMed Siggelkow H, Rebenstorff K, Kurre W et al (1999) Development of the osteoblast phenotype in primary human osteoblasts in culture: comparison with rat calvarial cells in osteoblast differentiation. J Cell Biochem 75(1):22–35CrossRefPubMed
31.
Zurück zum Zitat Festuccia C, Guerra F, D’Ascenzo S et al (1998) In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int J Cancer 75(3):418–431CrossRefPubMed Festuccia C, Guerra F, D’Ascenzo S et al (1998) In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int J Cancer 75(3):418–431CrossRefPubMed
Metadaten
Titel
Modulation of prostate cancer cell gene expression by cell-to-cell contact with bone marrow stromal cells or osteoblasts
verfasst von
Shuming Zhang
Jun Wang
Mehmet A. Bilen
Sue-Hwa Lin
Samuel I. Stupp
Robert L. Satcher
Publikationsdatum
01.12.2009
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 8/2009
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-009-9289-0

Weitere Artikel der Ausgabe 8/2009

Clinical & Experimental Metastasis 8/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.